Skip to main content

View full-text article in PMC

. 2009 Dec 14;12(1):95–103. doi: 10.1093/neuonc/nop015

Table 5.

Study population groups and erlotinib dose

Parameters	Non-EIAEDs (n = 76)^a (150 mg/d)	Phase I/II^b (n = 18) (150 mg/d)
C_max (ng/mL)	872 (±399)	983 (±500)
T_max (h)	3.0 (±1.9)	4.1 (±3.1)
AUC_0–24 (µg h/mL)	11.86 (±5.01)	12.94 (±4.56)
C_ss min (µg/mL)	0.98 (±0.54)	1.00 (±0.67)

^aCurrent study.

^bHerbst et al.³¹.